[ASC-list] Brisbane - AIBN Seminar - Professor Mark A. F. Kendall, AIBN Group Leader

Jayne Keane jayne.keane at qm.qld.gov.au
Tue Mar 12 04:03:49 UTC 2013


 

 

 

AIBN SEMINAR SERIES:

 

Presenter:

Professor Mark A. F. Kendall, AIBN Group Leader

Title: 

Improving the reach of vaccines to the developing world with Nanopatches

Time:

12:00pm

Venue:

Parnell Building 07, Lecture Room 222

  Date:                   Thursday 14 March 2013

 

Improving the reach of vaccines to the developing world with Nanopatches

Vaccines have produced one of the largest increases in the age of life
expectancy in human history. However massive challenges remain, with 17
million deaths per year due to infectious disease - mostly in the
developing-world.

I will discuss the particular challenges holding back vaccines within
the developing world; together with potential solutions under
development.

 

My particular focus will move to the needle and syringe: currently the
main vaccination method, which was first invented in 1853.  The needle
is holding back the rollout of vaccines by (1) placing vaccine into
muscle, arguably missing our immune "sweet spot"); (2) the need for
maintaining the refrigeration "cold chain" of the vaccine in liquid
form; and (3) cross-contamination through needle-stick injuries.

 

I will then introduce the Nanopatch - conceived to tackle all three of
these needle-based problems - and outline the Nanopatch journey from
idea towards clinical utility as a medical device product.  

 

Professor Mark A.F. Kendall has more than 15 years of experience
researching the field of needle-free gene and drug delivery to skin with
micro-nanostructures, authoring over 334 refereed journal, conference
papers, and presentations, including invited Keynote and Plenary
lectures in more than twenty countries, as well as served as Session
Moderators. In addition, Mark has been an inventor on more than 96
patents (with 4 more patent applications in process) and has worked
closely with Industrial partners in the technology transfer from concept
to commercialisation. His Biolistics technology has been successfully
commercialised with PowderMed (the technology transfer company)
purchased by Pfizer for $400 M in 2006. 

 

Mark joined the University of Queensland for a Professorial position
after 8 years at the University of Oxford, where he was Associate
Director of the PowderJect Centre for Gene and Drug Delivery Research, a
University Research Lecturer and College Lecturer (Magdalen College). He
was one of the youngest lecturers at Oxford. He is Co-Founder of Vaxxas,
a spin out company with $15 M of investment consortium funding to
commercialize the Nanopatch. In addition to research at UQ, Mark
lectures undergraduate students in biomedical fluid mechanics.  Most
recently, Mark was made a Rolex Laureate.  

 


******************* Disclaimer *******************
The contents of this electronic message and any attachments are intended only for the addressee and may contain privileged or confidential information. 
They may only be used for the purposes for which they were supplied.
If you are not the addressee, you are notified that any transmission, distribution, downloading, printing or photocopying of the contents of this message 
or attachments is strictly prohibited. 
The privilege of confidentiality attached to this message and attachments is not waived, lost or destroyed by reason of mistaken delivery to you. 
If you receive this message in error please notify the sender by return e-mail or telephone. 
Please note: the Queensland Museum carries out automatic software scanning, filtering and blocking of E-mails and
attachments (including emails of a personal nature) for detection of viruses, malicious code, SPAM, executable programs or content it deems unacceptable. 
All reasonable precautions will be taken to respect the privacy of individuals as outlined in the QM Privacy Plan. 
Personal information will only be used for official purposes, e.g. monitoring Departmental Personnel's compliance with Museum Policies. 
Personal information will not be divulged or disclosed to others, unless as required by Museum Policy and/or State or Commonwealth Law.
******************** Disclaimer *******************


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://www.lists.sublimeip.com/pipermail/asc-list/attachments/20130312/d6cc229d/attachment.htm>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image002.gif
Type: image/gif
Size: 3924 bytes
Desc: image002.gif
URL: <https://www.lists.sublimeip.com/pipermail/asc-list/attachments/20130312/d6cc229d/attachment.gif>


More information about the ASC-list mailing list